Impact of prior or concomitant seasonal influenza vaccination on MF59-adjuvanted H1N1v vaccine (Focetria™) in adult and elderly subjects

International Journal of Clinical Practice

Volumn 64, Issue 4, 2010, Pages 432-438

  Gasparini, R ^a   Schioppa, F ^b   Lattanzi, M ^c   Barone, M ^c   Casula, D ^c   Pellegrini, M ^c   Veitch, K ^c   Gaitatzis, N ^c  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c Novartis Vaccines and Diagnostics   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE;

ADULT; AGED; ARTHRALGIA; ARTICLE; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG APPROVAL; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; ECCHYMOSIS; FATIGUE; FEMALE; HEMAGGLUTINATION; HUMAN; IMMUNOGENICITY; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; MALAISE; MALE; MASS IMMUNIZATION; MULTICENTER STUDY; MYALGIA; NAUSEA; PRIORITY JOURNAL; SIDE EFFECT; SWEATING; VIRUS STRAIN;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; ANTIBODY FORMATION; FEMALE; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; POLYSORBATES; SEASONS; SQUALENE; YOUNG ADULT;

EID: 76349101141     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2009.02309.x     Document Type: Article

References (13)

1. Greenberg ME, Lai MH, Hartel GF et al. Response after one dose of a monovalent influenza A (H1N1) 2009 vaccine - preliminary report. N Engl J Med 2009 361. September 10: doi :.
2. Clark TW, Pareek M, Hoschler K et al. Trial of influenza A (H1N1) 2009 monovalent MF59-adjuvanted vaccine - preliminary report. N Engl J Med 2009 361. September 10: doi :.
3. Zhu FC, Wang H, Fang H-H et al. A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med 2009 361. October 21: doi :.
4. CHMP. Note for guidance on harmonisation of requirements for influenza vaccines (EMEA/CHMP/BWP/214/96) 12 March 1997.
5. CHMP. Guideline on cossier structure and content for pandemic influenza vaccine Marketing Authorisation Application (Revision; EMEA/CPMP/VEG/4717/2003- Rev 1) 18 December 2008
6. Bonhoeffer J, Bentsi-Enchill A, Chen RT et al. Guidelines for collection, analysis and presentation of vaccine safety data in pre- and post-licensure clinical studies. Vaccine 2009 27 : 2282 2288.
7. Rowe T, Abernathy RA, Hu-Primmer J et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 1999 37 : 937 943.
8. Pellegrini M, Nicolay U, Lindert K, Groth N, Della Cioppa G. MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database. Vaccine 2009 27 : 6959 6965.
9. Banzhoff A, Pellegrini M, Del Giudice G, Fragapane E, Groth N, Podda A. MF59-adjuvanted vaccines for seasonal and pandemic influenza prophylaxis. Influenza Other Respi Viruses 2008 2 : 243 249.
10. Hancock K, Veguilla V, Lu X et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009 361 : 1945 1952.
11. Anonymous. Effectiveness of 2008-09 trivalent influenza vaccine against 2009 pandemic influenza A (H1N1) - United States. MMWR 2009 58 : 1241 1245.
12. Anonymous. Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. MMWR 2009 58 : 521 524.
13. Tritto E, Mosca F, De Gregorio E. Mechanism of action of licensed vaccine adjuvants. Vaccine 2009 27 : 3331 3334.